Compare Eli Lilly And Co (LLY) vs Solaredge Technologies Inc (SEDG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Solaredge Technologies Inc — how do they compare? Eli Lilly And Co trades at $1,141 (market cap $1.02T), while Solaredge Technologies Inc trades at $49.88 (market cap $2.96B). The key difference: Eli Lilly And Co is far larger — about 344.6× Solaredge Technologies Inc's market cap, and Eli Lilly And Co pays a 0.6% dividend while Solaredge Technologies Inc pays none. Which is the better fit depends on your goals.
| LLY | SEDG | |
|---|---|---|
Market Cap | $1.02T | $2.96B |
Sector | Health | Technology |
52-Week High | $1.24K | $78.51 |
52-Week Low | $625.65 | $24.42 |
Enterprise Value | $1.06T | $2.89B |
Dividend Yield | 0.6% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.
Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.
SolarEdge Technologies (SEDG) trades at $48.65, down 9.01% in the last session, reflecting ongoing volatility. The stock shows a bearish technical signal with mixed earnings history—beating estimates in Q3 and Q4 2025 but missing in Q1 2026. Revenue declined to $1.18 billion in 2025, with a net loss of $405.45 million, though operating cash flow improved to $104.26 million. Analyst consensus is divided, with a hold-heavy rating and a $35.65 price target below the current price.
The outlook remains challenging due to persistent losses and competitive pressures, but potential catalysts include upcoming Q2 2026 earnings and demand for solar solutions. Key risks include high debt, margin pressures, and market sentiment shifts. Investors should weigh cost-cutting progress against sector headwinds for recovery potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Solaredge Technologies Inc
SolarEdge Technologies designs, develops, and sells direct current optimized inverter systems for solar photovoltaic installations. The company system consists of power optimizers, inverters, and cloud-based monitoring platform and addresses a broad range of solar market segments, from residential solar installations to commercial and small utility-scale solar installations. The company sells its products directly to solar installers, engineering, procurement, and construction firms and indirectly to solar installers through distributors and electrical equipment wholesalers. Additionally, the company has nonsolar products targeting energy storage and e-mobility.
Read more on SEDG →
